vimarsana.com
Home
Live Updates
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option : comparemela.com
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation.
Related Keywords
Boston ,
Massachusetts ,
United States ,
Ian Meredith ,
Exchange Commission ,
American College Of Cardiology Foundation ,
Twitter ,
Facebook ,
Securities Exchange ,
Boston Scientific ,
National Cardiovascular Data Registry ,
Left Atrial Appendage Closure ,
Left Atrial Appendage Occlusion Registry ,
American College ,
Cardiology Foundation ,
Recent Clinical Data Supporting ,
Securities Act ,
Securities Exchange Act ,
Risk Factors ,
Annual Report ,
Quarterly Reports ,
Food And Drug Administration ,
Forward Looking Statement ,
Healthcare ,
Linkedin ,
Medical Equipment ,
Medicine ,
Technology ,
Anticoagulant ,
Aspirin ,
Interventional Cardiology ,
Left Atrial Appendage Occlusion ,
Watchman ,
comparemela.com © 2020. All Rights Reserved.